Jifeng Feng

33.7k citations

288 papers · 8.6k indexed · 2 hit papers · h-index 44

Oncology top 0.5%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 0.5%
Surgery top 5%

Co-authors: Jian WuShaorong Yu Yi‐Long Wu Shun Lü Chengping Hu Caicun Zhou Mei Hou Wěi Li
Topics: Lung Cancer Treatments and Mutations (59 papers)Cancer-related molecular mechanisms research (43 papers)Lung Cancer Research Studies (37 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Biological Chemistry Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: China United States United Kingdom

In The Last Decade

Jifeng Feng

276 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

2014 1.6k citations Jifeng Feng, Wěi Li et al. profile →
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

2014 474 citations Rui‐Hua Xu, Jin Li et al. profile →

Peers

Countries citing papers authored by Jifeng Feng

Since Specialization

Citations

This map shows the geographic impact of Jifeng Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jifeng Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jifeng Feng more than expected).

Fields of papers citing papers by Jifeng Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jifeng Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jifeng Feng. The network helps show where Jifeng Feng may publish in the future.

Co-authorship network of co-authors of Jifeng Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Jifeng Feng. A scholar is included among the top collaborators of Jifeng Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jifeng Feng. Jifeng Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis 2024 ·Anti-Cancer Agents in Medicinal Chemistry ·Dan Zou,(unknown),(unknown),(unknown),Bei Zhong,Bo Shen,Yuxin Du,Jifeng Feng	0
2	Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy 2023 ·PubMed ·Xiaojia Wang,Wěi Li,Yongmei Yin,Zhongsheng Tong,Qingyuan Zhang,Hong Zheng,(unknown),Huiping Li,Yang Jin,Jifeng Feng,Fan Wu,(unknown),Eleonora Restuccia,Zefei Jiang	4
3	Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study) 2023 ·European Journal of Cancer ·Jiayu Wang,Li Cai,Yanqiu Song,Tong Sun,Zhongsheng Tong,Yuee Teng,Huiping Li,Quchang Ouyang,Qianjun Chen,Shude Cui,Yongmei Yin,Ning Liao,Qiang Sun,Jifeng Feng,Xiaojia Wang,Binghe Xu	7
4	The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy 2023 ·Cell Communication and Signaling ·Yan Lv,Yuxin Du,Kening Li,Xiao Ma,Juan Wang,(unknown),(unknown),Yue Teng,(unknown),Rong Ma,Jianqiu Wu,Jian Wu,Jifeng Feng	9
5	Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial 2023 ·Signal Transduction and Targeted Therapy ·Yunpeng Yang,Jie Min,Nong Yang,(unknown),Ying Cheng,Yanqiu Zhao,Manxiang Li,(unknown),(unknown),Jianying Zhou,Wu Zhuang,(unknown),Lejie Cao,Yan Yu,Jiän Zhang,Jianxing He,Jifeng Feng,Hao Yu,Li Zhang,Wenfeng Fang	15
6	An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma 2023 ·Cancer Cell ·Yan‐Xing Chen,Zixian Wang,Ying Jin,Qi Zhao,Zexian Liu,Zhixiang Zuo,Huai‐Qiang Ju,Chengxu Cui,Jun Yao,Yanqiao Zhang,Mengxia Li,Jifeng Feng,Lin Tian,Xiaojun Xia,Hui Feng,Sheng Yao,Feng‐Hua Wang,Yuhong Li,Rui Wang,Rui‐Hua Xu	22
7	SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study 2022 ·Clinical Cancer Research ·Jifeng Feng,(unknown),Jing Wang,Qi Zhou,(unknown),Hanmei Lou,Yuping Sun,(unknown),Hongmin Chen,Junqin Yang,Pan Liu,Linna Wang,Jianjun Zou	42
8	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study 2022 ·Breast Cancer Research and Treatment ·Binghe Xu,Wěi Li,Qingyuan Zhang,Qiao Li,Xiaojia Wang,Huiping Li,Tao Sun,Yongmei Yin,Hong Zheng,Jifeng Feng,(unknown),(unknown),(unknown),Adam Knott	18
9	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study 2020 ·Clinical Cancer Research ·Ligang Xing,Yueyin Pan,Yuankai Shi,Yongqian Shu,Jifeng Feng,Wěi Li,Lejie Cao,Lifeng Wang,Wei Gu,Yong Song,Puyuan Xing,Yutao Liu,Wen Gao,Jiuwei Cui,(unknown),Rutian Li,Hua Bao,Yang Shao,Jinming Yu	28
10	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study 2020 ·Breast Cancer Research and Treatment ·Binghe Xu,Wei Li,Qingyuan Zhang,Zhimin Shao,Qiao Li,Xiaojia Wang,Huiping Li,Tao Sun,Yongmei Yin,Hong Zheng,Jifeng Feng,Hong Zhang,Guiyuan Lei,Eleonora Restuccia	29
11	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Yuqin Song,Jianqiu Wu,Xinchuan Chen,Tongyu Lin,Junning Cao,Yanyan Liu,Yaozhong Zhao,Jie Jin,Haiwen Huang,Jianda Hu,(unknown),Liling Zhang,Hong‐Wei Xue,Qingyuan Zhang,Weiwei Wang,(unknown),Jifeng Feng,Jun Zhu	109
12	miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy 2019 ·Gut ·Wenping Xu,Jinpei Liu,Jifeng Feng,Changpeng Zhu,Yuan Yang,Weiping Zhou,Jin Ding,Chenkai Huang,(unknown),Chen‐Hong Ding,Xin Zhang,Bin Lü,Wei‐Fen Xie	88
13	Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in nonsmall cell lung cancer cell lines 2019 ·Translational Cancer Research ·(unknown),Bo Shen,Xiaobing Qin,Siwen Liu,Jifeng Feng	6
14	Prognostic significance of PD-L1 expression in patients with colorectal cancer: a meta-analysis* 2019 ·Oncology and Translational Medicine ·Siwen Liu,Rong Ma,Haixia Cao,Dan Chen,Changwen Jing,Zhuo Wang,Junying Zhang,Yang‐Chang Wu,Jifeng Feng,Jian Wu	0
15	Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China 2017 ·The Oncologist ·Jianbin Li,Shusen Wang,Yongsheng Wang,Xiaojia Wang,Haibo Wang,Jifeng Feng,Qingyuan Zhang,Tao Sun,Quchang Ouyang,Yongmei Yin,Yinhua Liu,Cuizhi Geng,Min Yan,Zefei Jiang	35
16	Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807) 2015 ·Medicine ·Hong-Yun Zhao,Gongyan Chen,Yan Huang,Xiaoli Li,Jifeng Feng,Meiqi Shi,Ying Cheng,(unknown),Yiping Zhang,Cuiping Gu,(unknown),(unknown),Li Zhang	2
17	Expression of β2 microglobin and vascular endothelial growth factors in diffuse large B-cell lymphoma and its clinical significance 2013 ·Jian Wu,Yuejiao Zhong,Rong Ma,Haixia Cao,Zhuo Wang,Changwen Jing,Jifeng Feng	1
18	Relationgship of genetic polymorphisms of ERCC1 with the clinical prognosis to platin-based chemotherapy in patients with advanced non-small cell lung cancer 2013 ·(unknown),Jifeng Feng,Jianwei Lu	1
19	Polymorphisms in XPD751 gene and sensitivity to Gemcitabine/Cisplatin chemotherapy in advanced stage of non-small-cell lung cancer 2008 ·Jifeng Feng	2
20	[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. 2008 ·PubMed ·Mei Dong,Feng-yi Feng,Yang Zhang,(unknown),Yajie Wang,Jiwei Liu,Santai Song,Qinghua Zhou,Jun Ren,Shunchang Jiao,Jin Li,Xiuwen Wang,Qiang Chen,Zhehai Wang,Nong Xu,Jifeng Feng	4

About Jifeng Feng

Jifeng Feng is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 288 papers that have together received 8.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (59 papers), Cancer-related molecular mechanisms research (43 papers) and Lung Cancer Research Studies (37 papers). The work is most often cited by research in Cancer Research (2.9k citations), Oncology (4.1k citations) and Pulmonary and Respiratory Medicine (3.8k citations). Jifeng Feng has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jian Wu, Shaorong Yu, Yi‐Long Wu, Shun Lü, Chengping Hu, Caicun Zhou, Mei Hou, Wěi Li, Yunchao Huang and Dan Massey. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact